Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability

Abstract

The EPH/EFN family of receptor tyrosine kinases regulates cell adhesion and migration and has an important role in controlling cell positioning in the normal intestinal epithelium. Inactivation of EPHB2 has recently been shown to accelerate tumorigenesis in the colon and rectum, and we have previously demonstrated frequent frameshift mutations (41%) in an A9 coding microsatellite repeat in exon 17 of EPHB2 in colorectal tumors with microsatellite instability (MSI). In this study, we extended these analyses to extracolonic MSI cancers, and found frameshift EPHB2 mutations in 39% (25/64) of gastric tumors and 14% (8/56) of endometrial tumors. Regression analysis of these EPHB2 mutation data on the basis of our previously proposed statistical model identified EPHB2 as a selective target of frameshift mutations in MSI gastric cancers but not in MSI endometrial carcinomas. These results suggest a functional role for EPHB2 in gastric tumor progression, and emphasize the differences between the tumorigenic processes in MSI gastrointestinal and endometrial cancer.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  • Alazzouzi H, Davalos V, Kokko A, Domingo E, Woerner SM, Wilson AJ et al. (2005). Cancer Res 65: 10170–10173.

  • Batlle E, Bacani J, Begthel H, Jonkeer S, Gregorieff A, van de Born M et al. (2005). Nature 435: 1126–1130.

  • Batlle E, Henderson JT, Beghtel H, van den Born MM, Sancho E, Huls G et al. (2002). Cell 111: 251–263.

  • Bilbao C, Rodriguez G, Ramirez R, Falcon O, Leon L, Chirino R et al. (2006). Int J Cancer 119: 563–570.

  • Duval A, Reperant M, Compoint A, Seruca R, Ranzani GN, Iacopetta B et al. (2002). Cancer Res 62: 1609–1612.

  • Elowe S, Holland SJ, Kulkarni S, Pawson T . (2001). Mol Cell Biol 21: 7429–7441.

  • Gerety SS, Wang HU, Chen ZF, Anderson DJ . (1999). Mol Cell 4: 403–414.

  • Guo DL, Zhang J, Yuen ST, Tsui WY, Chan ASY, Ho C et al. (2006). Carcinogenesis 27: 454–464.

  • Henkemeyer M, Orioli D, Henderson JT, Saxton TM, Roder J, Pawson T et al. (1996). Cell 86: 35–46.

  • Holder N, Klein R . (1999). Development 126: 2033–2044.

  • Huet S, Bouvier A, Gruet M, Jolivet E . (2003). Statistical Tools for Nonlinear Regression. A Practical Guide with S-PLUS Examples, 2nd edn. Springer: New York, USA.

    Google Scholar 

  • Lugli A, Spichtin H, Maurer R, Mirlacher M, Kiefer J, Huusko P et al. (2005). Clin Cancer Res 11: 6450–6458.

  • Schwartz Jr S, Yamamoto H, Navarro M, Maestro M, Reventos J, Perucho M . (1999). Cancer Res 59: 2995–3002.

  • Woerner SM, Benner A, Sutter C, Schiller M, Yuan YP, Keller G et al. (2003). Oncogene 22: 2226–2235.

  • Yamamoto H, Itoh F, Fukushima H, Adachi Y, Itoh H, Hinoda Y et al. (1999). J Exp Clin Cancer Res 18: 103–106.

Download references

Acknowledgements

This study was partly funded by grants from the Spanish Fondo de Investigaciones Sanitarias (FIS PI051394) and from the FMM to DA; Deutsche Krebshilfe Grant (Kn) to JG and SW; Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan to HY and KI, POCTI/SAU-OBS/56921/2004 da Fundação para a Ciência e a Tecnologia of Portugal to RS, NIH, Grant number R37 CA63585 to MP; and ICIC, Fondo de Investigaciones Sanitarias (FIS-ISCiii-RTICCC), Fundación Canaria de Investigación y Salud (FUNCIS) and Dirección General de Universidades del Gobierno de Canarias to N D-C and JC D-C, grant from Fundação para a Ciência e a Tecnologia, Portugal to AMF and Grants-in-Aid for Cancer Research and for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare of Japan to HY and KI. VD is supported by a predoctoral fellowship from the Vall d'Hebron Research Institute.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D Arango.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davalos, V., Dopeso, H., Velho, S. et al. High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene 26, 308–311 (2007). https://doi.org/10.1038/sj.onc.1209780

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209780

Keywords

This article is cited by

Search

Quick links